Market Challenges And Opportunities

However, factors such as side-effects of inhaler anesthesia drugs and increase in demand or adoption of generics are expected to hamper the market growth.

Global Inhalation Anesthesia Market Drivers:

Rise in burden of chronic diseases to drive market growth

One of the key factors expected to augment the growth of the global inhalation anesthesia market over the forecast period is the increasing prevalence of chronic disease, such as heart disease and cancer across the world. Such a high burden of chronic diseases leads to an increase in the number of surgeries and is expected to fuel the market growth. According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of death across the globe, taking an estimated 17.9 million lives each year, driving the growth of the market.

Growing geriatric population to propel market growth

Another factor which is driving growth of the global inhalation anesthesia market is the growing geriatric (aging) population around the world. For instance, the aging population tends to have a higher prevalence of chronic diseases. People age 65 and older are more likely than younger people to suffer from chronic disease. According to the World Health Organization (WHO), by 2030, one in six people in the world will be aged 60 years or over, and by 2050, the world’s population of people aged 60 years and older will double (2.1 billion).

Global Inhalation Anesthesia Market Opportunities:

Outbreak of COVID-19 (pandemic) is expected to offer lucrative growth opportunities for players in the global inhalation anesthesia market. For instance, the application of inhalation Anesthesia for the diagnosis and treatment of COVID-19 and associated diseases has positively impacted the market growth. Inhaled agents may provide important pulmonary benefits for COVID-19 patients with ARDS that could improve gas exchange and reduce time spent on a ventilator. Administration of inhalation Anesthesia for sedation during longer-term ventilation with anesthesia machines has also been reported in a few institutions.

Increase in demand or consumption of inhalation anesthesia is expected to offer significant growth opportunities for players in the global inhalation anesthesia market. For instance, with the increase in burden of chronic disease and increasing number of surgical procedures, the demand or the use of inhalation anesthesia is also increasing with the rapid pace. In February 2022, Sedana Medical AB announced the launch of Sedaconda (isoflurane) in Germany. Sedaconda has received national approvals in around 15 countries, and is also expected to receive national approvals in Switzerland, Poland, Italy, and the United Kingdom.

Global Inhalation Anesthesia Market Restraints:

Side-effects of Anesthesia to hinder market growth

One of the key factors expected to hamper growth of the global inhalation anesthesia market is the side-effects of inhaler anesthesia drugs. For instance, inhalation anesthetics have a diverse range of clinically significant effects on several organs, both beneficial and potentially adverse. Adverse or side-effects of inhalation anesthetics include neurotoxicity, nephrotoxicity, cardiac arrhythmias, hepatotoxicity, respiratory depression, irritation, postanesthesia agitation, malignant hyperthermia, and postoperative nausea and vomiting, among others.

Rise in adoption of generics to hamper market growth

Another factor which is hampering the growth of the global inhalation anesthesia market is the rise in demand or adoption of generic inhalation anesthetic drugs. Some players in market are focusing on launching generic inhalation anesthetic drugs in the market, but the launch of generic inhalation anesthetic drugs may decrease the use or demand of patented inhalation anesthetics. Moreover, the use or demand of generic drugs is increasing as they are cheaper compared to the patented drugs. This in turn is also expected to hinder growth of the market.